HLA-A and neoplasm: Evaluating the reciprocal group of patients with low (below median) HLA-A expression, where the potential of immunogenic mutations to elicit bona fide anti-tumor responses is expected to be curtailed, there was no significant association between the presence of predicted immunogenic mutations and survival (HR = 1.30, 95% CI = 0.83 to 2.04, P = 2.6 × 10−1).